Future Targeted Healthcare Manufacturing Hub

Biomanufacturing solutions to transform healthcare precision in the biotherapeutics sector

What will the Future Targeted Healthcare Manufacturing Hub deliver and achieve?

View launch presentations here...(please contact eleanor.bonnist@ucl.ac.uk for password)

UCL Biochemical Engineering has an outstanding track record and is a world leader in bioprocess research across a range of sectors. UCL’s Future Targeted Healthcare Manufacturing Hub engages leading academics across the UK as Spokes. This national asset is valued in excess of £20M over 7 years (2017–2024).

The Hub will address the manufacturing, business and regulatory challenges to ensure that new targeted biological medicines can be developed quickly and manufactured at a cost affordable to society.

The research will span stratified protein medicines targeted to particular patient groups through to truly personalised cell-based medicines.

The Hub is unique in the biomanufacturing space, and is being supported by a large number of the leading manufacturers and suppliers in the biotherapeutics industry and non-governmental associations.

How can stratified proteins and personal cell therapies achieve success in manufacturing and business?

Further information

Contact

For more information on the Hub, collaboration and how join the industrial consortium please contact:

Dr Naveraj Gill, Strategic Alliance Director, Deputy Head of Department (Enterprise) E: naveraj.gill@ucl.ac.uk T: +44 (0) 203 549 5619

Research Excellence

Access to internationally-leading academics and top research graduates with expertise in bioprocessing, decisional tools, process control and analytics, cell therapy manufacture.

Wider collaboration opportunities within the Hub User Group via Engineering Doctorate (EngD) studentships.

Opportunity to create a Centre of Excellence with UCL focusing on a series of linked research projects for a more holistic and synergistic approach.

Influence in the Sector

Steer the research agenda over the next 7 years, aligned to your organisation’s priorities.

Participate in user feasibility projects to evaluate Hub outputs using your systems and processes.

Boost your profile through joint peer-reviewed articles from user feasibility projects.

Leverage funding for greater impact via industry-led InnovateUK projects.

Priority Access to Hub Outputs

Early access to new process, analysis and control technologies and methodologies via the Collaboration Agreement and IP provisions.

Benefit from novel decision-support tools providing a robust framework for selecting development and manufacturing options, thus reducing the risk of misallocating significant cost and time.

Access to highly skilled graduating doctoral and PDRA researchers.